Nipat Chuleerarux1, Achitpol Thongkam2, Kasama Manothummetha2, Saman Nematollahi3, Veronica Dioverti-Prono3, Pattama Torvorapanit4, Nattapong Langsiri2, Navaporn Worasilchai5, Rongpong Plongla4, Ariya Chindamporn2, Anawin Sanguankeo6, Nitipong Permpalung2,3. 1. Department of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. 2. Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. 3. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 4. Department of Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand. 5. Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand. 6. Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Abstract
BACKGROUND: Cytomegalovirus (CMV) and invasive aspergillosis (IA) cause high morbidity and mortality in solid organ transplant (SOT) recipients. There are conflicting data with respect to the impact of CMV on IA development in SOT recipients. METHODS: A literature search was conducted from existence through to 2 April 2021 using MEDLINE, Embase, and ISI Web of Science databases. This review contained observational studies including cross-sectional, prospective cohort, retrospective cohort, and case-control studies that reported SOT recipients with post-transplant CMV (exposure) and without post-transplant CMV (non-exposure) who developed or did not develop subsequent IA. A random-effects model was used to calculate the pooled effect estimate. RESULTS: A total of 16 studies were included for systematic review and meta-analysis. There were 5437 SOT patients included in the study, with 449 SOT recipients developing post-transplant IA. Post-transplant CMV significantly increased the risk of subsequent IA with pORs of 3.31 (2.34, 4.69), I2 = 30%. Subgroup analyses showed that CMV increased the risk of IA development regardless of the study period (before and after 2003), types of organ transplantation (intra-thoracic and intra-abdominal transplantation), and timing after transplant (early vs. late IA development). Further analyses by CMV definitions showed CMV disease/syndrome increased the risk of IA development, but asymptomatic CMV viremia/infection did not increase the risk of IA. Conclusions: Post-transplant CMV, particularly CMV disease/syndrome, significantly increased the risks of IA, which highlights the importance of CMV prevention strategies in SOT recipients. Further studies are needed to understand the impact of programmatic fungal surveillance or antifungal prophylaxis to prevent this fungal-after-viral phenomenon.
BACKGROUND: Cytomegalovirus (CMV) and invasive aspergillosis (IA) cause high morbidity and mortality in solid organ transplant (SOT) recipients. There are conflicting data with respect to the impact of CMV on IA development in SOT recipients. METHODS: A literature search was conducted from existence through to 2 April 2021 using MEDLINE, Embase, and ISI Web of Science databases. This review contained observational studies including cross-sectional, prospective cohort, retrospective cohort, and case-control studies that reported SOT recipients with post-transplant CMV (exposure) and without post-transplant CMV (non-exposure) who developed or did not develop subsequent IA. A random-effects model was used to calculate the pooled effect estimate. RESULTS: A total of 16 studies were included for systematic review and meta-analysis. There were 5437 SOT patients included in the study, with 449 SOT recipients developing post-transplant IA. Post-transplant CMV significantly increased the risk of subsequent IA with pORs of 3.31 (2.34, 4.69), I2 = 30%. Subgroup analyses showed that CMV increased the risk of IA development regardless of the study period (before and after 2003), types of organ transplantation (intra-thoracic and intra-abdominal transplantation), and timing after transplant (early vs. late IA development). Further analyses by CMV definitions showed CMV disease/syndrome increased the risk of IA development, but asymptomatic CMV viremia/infection did not increase the risk of IA. Conclusions: Post-transplant CMV, particularly CMV disease/syndrome, significantly increased the risks of IA, which highlights the importance of CMV prevention strategies in SOT recipients. Further studies are needed to understand the impact of programmatic fungal surveillance or antifungal prophylaxis to prevent this fungal-after-viral phenomenon.
Authors: Nina Singh; Robin K Avery; Patricia Munoz; Timothy L Pruett; Barbara Alexander; Richard Jacobs; Jan G Tollemar; Edward A Dominguez; Chen M Yu; David L Paterson; Shahid Husain; Shimon Kusne; Peter Linden Journal: Clin Infect Dis Date: 2002-12-13 Impact factor: 9.079
Authors: R N Husni; S M Gordon; D L Longworth; A Arroliga; P C Stillwell; R K Avery; J R Maurer; A Mehta; T Kirby Journal: Clin Infect Dis Date: 1998-03 Impact factor: 9.079
Authors: Pierre-Yves Bochud; Jason W Chien; Kieren A Marr; Wendy M Leisenring; Arlo Upton; Marta Janer; Stephanie D Rodrigues; Sarah Li; John A Hansen; Lue Ping Zhao; Alan Aderem; Michael Boeckh Journal: N Engl J Med Date: 2008-10-23 Impact factor: 91.245
Authors: F López-Medrano; J T Silva; M Fernández-Ruiz; P L Carver; C van Delden; E Merino; M J Pérez-Saez; M Montero; J Coussement; M de Abreu Mazzolin; C Cervera; L Santos; N Sabé; A Scemla; E Cordero; L Cruzado-Vega; P L Martín-Moreno; Ó Len; E Rudas; A Ponce de León; M Arriola; R Lauzurica; M David; C González-Rico; F Henríquez-Palop; J Fortún; M Nucci; O Manuel; J R Paño-Pardo; M Montejo; P Muñoz; B Sánchez-Sobrino; A Mazuecos; J Pascual; J P Horcajada; T Lecompte; C Lumbreras; A Moreno; J Carratalà; M Blanes; D Hernández; E A Hernández-Méndez; M C Fariñas; M Perelló-Carrascosa; J M Morales; A Andrés; J M Aguado Journal: Am J Transplant Date: 2016-03-10 Impact factor: 8.086
Authors: Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: BMJ Date: 2015-01-02